Metformin pathways: pharmacokinetics and pharmacodynamics
Background Metformin is a first-line therapy for type 2 diabetes mellitus (T2DM, formerly 'non-
insulin-dependent diabetes mellitus'), and is one of the most commonly prescribed drugs
worldwide. As a biguanide agent, metformin lowers both basal and postprandial plasma
glucose (PPG) 1, 2. It can be used as a monotherapy or in combination with other
antidiabetic agents including sulfonylureas, α-glucosidase inhibitors, insulin,
thiazolidinediones, DPP-4 inhibitors as well as GLP-1 agonists. Metformin works by …
insulin-dependent diabetes mellitus'), and is one of the most commonly prescribed drugs
worldwide. As a biguanide agent, metformin lowers both basal and postprandial plasma
glucose (PPG) 1, 2. It can be used as a monotherapy or in combination with other
antidiabetic agents including sulfonylureas, α-glucosidase inhibitors, insulin,
thiazolidinediones, DPP-4 inhibitors as well as GLP-1 agonists. Metformin works by …
